“…Second, computed tomography technology, the imaging modality that is most commonly used to investigate known or suspected pancreatic tumours, has improved. As a result, it has become increasingly common to identify pancreatic neuroendocrine tumours, with a detection rate exceeding 80% [10]. Finally, although overall survival for patients with pancreatic neuroendocrine tumours is more favourable than for patients with pancreatic adenocarcinomas, the median overall survival in metastatic disease does not exceed 2-5.8 years [11,12].…”